JP2008505107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505107A5 JP2008505107A5 JP2007519458A JP2007519458A JP2008505107A5 JP 2008505107 A5 JP2008505107 A5 JP 2008505107A5 JP 2007519458 A JP2007519458 A JP 2007519458A JP 2007519458 A JP2007519458 A JP 2007519458A JP 2008505107 A5 JP2008505107 A5 JP 2008505107A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- composition
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 17
- 208000035475 disorder Diseases 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 206010047700 Vomiting Diseases 0.000 claims 6
- -1 monosubstituted phenyl Chemical group 0.000 claims 6
- 206010028813 Nausea Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 230000008693 nausea Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000032841 Bulimia Diseases 0.000 claims 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 4
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 4
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000003862 glucocorticoid Substances 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 102400000096 Substance P Human genes 0.000 claims 2
- 101800003906 Substance P Proteins 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 208000029162 bladder disease Diseases 0.000 claims 2
- 208000022371 chronic pain syndrome Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000002762 nociceptin receptor agonist Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000008058 pain sensation Effects 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 229940122783 Endothelin converting-enzyme inhibitor Drugs 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229940117029 Melanocortin receptor agonist Drugs 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 101000955470 Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) ABC multidrug transporter MDR5 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002857 endothelin converting enzyme inhibitor Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000336 melanocortin receptor agonist Substances 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 239000003590 rho kinase inhibitor Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000002485 serotonin 2C agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- MCDJFTGQIMMZTN-UHFFFAOYSA-O CCNC(CC(CC1)(C[NH2+]C1(COC(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C1=CCCC=C1)N(C=NN1)C1=O)=O Chemical compound CCNC(CC(CC1)(C[NH2+]C1(COC(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C1=CCCC=C1)N(C=NN1)C1=O)=O MCDJFTGQIMMZTN-UHFFFAOYSA-O 0.000 description 1
- MTDHOWSBMVFTTA-YKQNXRHISA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC#C[C@](CC1)(c2ccccc2)NC[C@@]1(COC)N(CC(N1)=O)C1=O Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC#C[C@](CC1)(c2ccccc2)NC[C@@]1(COC)N(CC(N1)=O)C1=O MTDHOWSBMVFTTA-YKQNXRHISA-N 0.000 description 1
- ZAEIIBVTSYJROI-UPKQVVFYSA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@H]1N(C=NN1)C1=O Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@H]1N(C=NN1)C1=O ZAEIIBVTSYJROI-UPKQVVFYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58450204P | 2004-07-01 | 2004-07-01 | |
| PCT/US2005/023427 WO2006007540A2 (en) | 2004-07-01 | 2005-06-29 | Piperidine derivatives as nk1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505107A JP2008505107A (ja) | 2008-02-21 |
| JP2008505107A5 true JP2008505107A5 (OSRAM) | 2008-07-17 |
Family
ID=35453353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519458A Pending JP2008505107A (ja) | 2004-07-01 | 2005-06-29 | Ｎｋ１アンタゴニストとしてのピペリジン誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7709641B2 (OSRAM) |
| EP (3) | EP1799666B1 (OSRAM) |
| JP (1) | JP2008505107A (OSRAM) |
| KR (1) | KR101228282B1 (OSRAM) |
| CN (1) | CN101006074B (OSRAM) |
| AR (2) | AR049655A1 (OSRAM) |
| AU (1) | AU2005262330B2 (OSRAM) |
| BR (1) | BRPI0512958A (OSRAM) |
| CA (1) | CA2570197C (OSRAM) |
| EC (1) | ECSP067123A (OSRAM) |
| ES (2) | ES2576555T3 (OSRAM) |
| HK (1) | HK1247610A1 (OSRAM) |
| HU (1) | HUE027791T2 (OSRAM) |
| IL (1) | IL180329A0 (OSRAM) |
| MX (1) | MX2007000030A (OSRAM) |
| MY (1) | MY142804A (OSRAM) |
| NO (1) | NO340368B1 (OSRAM) |
| NZ (1) | NZ552059A (OSRAM) |
| PE (1) | PE20060483A1 (OSRAM) |
| PL (1) | PL1799666T3 (OSRAM) |
| PT (1) | PT1799666E (OSRAM) |
| RU (1) | RU2408591C9 (OSRAM) |
| SG (2) | SG154443A1 (OSRAM) |
| TW (1) | TWI348467B (OSRAM) |
| WO (1) | WO2006007540A2 (OSRAM) |
| ZA (1) | ZA200610666B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| AR049655A1 (es) * | 2004-07-01 | 2006-08-23 | Schering Corp | Antagonistas de nk1 |
| EP2997964A1 (en) | 2006-04-05 | 2016-03-23 | OPKO Health, Inc. | Pharmaceutical formulations comprising salts of (5s,8s)-8-[{(1 r)-1-(3,5-bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one and their medical use |
| PL2004646T3 (pl) | 2006-04-05 | 2016-12-30 | Chlorowodorek 8-[{l-(3,5-bis(trifluorometylo)fenylo)-etoksy}-metylol-8-fenylo-1,7-diaza-spiro[4.5]dekan-2-onu i sposób jego otrzymywania | |
| AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| EP2175886A1 (en) * | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| CN102203062B (zh) | 2008-09-05 | 2014-12-17 | 欧科生医股份有限公司 | 用于合成8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮化合物的方法和中间体 |
| WO2011019911A1 (en) * | 2009-08-14 | 2011-02-17 | Opko Health, Inc. | Intravenous formulations of neurokinin-1 antagonists |
| KR20120130078A (ko) * | 2009-11-09 | 2012-11-28 | 메디비르 아베 | 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도 |
| BR112012029227B1 (pt) | 2010-05-19 | 2020-01-07 | Sandoz Ag | Processo para a preparação de um composto quiral, composto quiral e uso de um composto |
| CN102892762B (zh) | 2010-05-19 | 2016-04-20 | 桑多斯股份公司 | 制备泊沙康唑中间体 |
| BR112012029225B1 (pt) | 2010-05-19 | 2020-10-27 | Sandoz Ag | processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral |
| MX2012013331A (es) | 2010-05-19 | 2013-02-01 | Sandoz Ag | Purificacion de posaconazol y de intermediarios de posaconazol. |
| CA2838051C (en) | 2011-06-16 | 2019-09-24 | Sandoz Ag | Process for the preparation of a chiral compound |
| JP2014530249A (ja) | 2011-10-18 | 2014-11-17 | ヘルシン ヘルスケア ソシエテ アノニム | ネツピタントおよびパロノセトロンの治療学的組合せ |
| JP2018520172A (ja) * | 2015-07-15 | 2018-07-26 | オプコ ヘルス インコーポレイテッド | 疾患の治療のためのヘテロアリールカルボニトリル |
| CN108148060B (zh) * | 2016-12-05 | 2020-06-19 | 四川科伦博泰生物医药股份有限公司 | 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途 |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| CN114958325B (zh) * | 2021-02-24 | 2023-06-27 | 中国石油化工股份有限公司 | 一种耐高温缓蚀剂、制备方法及其在井筒防腐中的应用 |
| JP2025535295A (ja) | 2022-10-18 | 2025-10-24 | ファイザー・インク | パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子 |
| EP4604955A1 (en) | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| US5620989A (en) | 1992-10-28 | 1997-04-15 | Merck Sharp & Dohme Limited | 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits |
| AU682838B2 (en) * | 1992-12-14 | 1997-10-23 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| EP0739336B1 (en) | 1994-01-13 | 1998-08-26 | MERCK SHARP & DOHME LTD. | Gem-disubstituted azacyclic tachykinin antagonists |
| EP0912174B1 (en) | 1996-07-17 | 2004-04-28 | MERCK & CO., INC. | Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists |
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| CA2287397A1 (en) | 1997-04-24 | 1998-10-29 | Merck Sharp & Dohme Limited | Use of an nk-1 receptor antagonist and an ssri for treating obesity |
| US6436928B1 (en) * | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
| MXPA04004477A (es) * | 2001-11-13 | 2004-08-11 | Schering Corp | Antagonistas del neuropeptido neuroquinina-1(nk1). |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| AR049655A1 (es) | 2004-07-01 | 2006-08-23 | Schering Corp | Antagonistas de nk1 |
-
2005
- 2005-06-29 AR ARP050102686A patent/AR049655A1/es not_active Application Discontinuation
- 2005-06-29 AU AU2005262330A patent/AU2005262330B2/en not_active Ceased
- 2005-06-29 MX MX2007000030A patent/MX2007000030A/es active IP Right Grant
- 2005-06-29 SG SG200904485-0A patent/SG154443A1/en unknown
- 2005-06-29 MY MYPI20052967A patent/MY142804A/en unknown
- 2005-06-29 HU HUE05787862A patent/HUE027791T2/en unknown
- 2005-06-29 CA CA2570197A patent/CA2570197C/en not_active Expired - Fee Related
- 2005-06-29 ES ES05787862.1T patent/ES2576555T3/es not_active Expired - Lifetime
- 2005-06-29 ES ES12169655.3T patent/ES2632413T3/es not_active Expired - Lifetime
- 2005-06-29 KR KR1020067027877A patent/KR101228282B1/ko not_active Expired - Fee Related
- 2005-06-29 EP EP05787862.1A patent/EP1799666B1/en not_active Expired - Lifetime
- 2005-06-29 SG SG2012096624A patent/SG187416A1/en unknown
- 2005-06-29 BR BRPI0512958-3A patent/BRPI0512958A/pt not_active Application Discontinuation
- 2005-06-29 RU RU2007103611/04A patent/RU2408591C9/ru not_active IP Right Cessation
- 2005-06-29 WO PCT/US2005/023427 patent/WO2006007540A2/en not_active Ceased
- 2005-06-29 NZ NZ552059A patent/NZ552059A/en not_active IP Right Cessation
- 2005-06-29 PL PL05787862.1T patent/PL1799666T3/pl unknown
- 2005-06-29 EP EP17165369.4A patent/EP3269713A1/en not_active Withdrawn
- 2005-06-29 CN CN2005800285965A patent/CN101006074B/zh not_active Expired - Fee Related
- 2005-06-29 EP EP12169655.3A patent/EP2522664B1/en not_active Expired - Lifetime
- 2005-06-29 JP JP2007519458A patent/JP2008505107A/ja active Pending
- 2005-06-29 PT PT05787862T patent/PT1799666E/pt unknown
- 2005-06-30 TW TW094122193A patent/TWI348467B/zh not_active IP Right Cessation
- 2005-06-30 US US11/172,289 patent/US7709641B2/en active Active
- 2005-06-30 PE PE2005000764A patent/PE20060483A1/es active IP Right Grant
-
2006
- 2006-12-18 ZA ZA200610666A patent/ZA200610666B/xx unknown
- 2006-12-25 IL IL180329A patent/IL180329A0/en not_active IP Right Cessation
- 2006-12-27 EC EC2006007123A patent/ECSP067123A/es unknown
-
2007
- 2007-01-31 NO NO20070588A patent/NO340368B1/no not_active IP Right Cessation
-
2010
- 2010-03-30 US US12/750,420 patent/US8026364B2/en not_active Expired - Lifetime
-
2011
- 2011-09-26 US US13/245,403 patent/US8754216B2/en not_active Expired - Lifetime
-
2014
- 2014-06-13 US US14/304,163 patent/US9469629B2/en not_active Expired - Fee Related
-
2016
- 2016-02-29 AR ARP160100524A patent/AR103812A2/es unknown
- 2016-10-14 US US15/293,962 patent/US9969711B2/en not_active Expired - Lifetime
-
2018
- 2018-03-28 US US15/938,409 patent/US20180215729A1/en not_active Abandoned
- 2018-05-28 HK HK18106977.4A patent/HK1247610A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008505107A5 (OSRAM) | ||
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| JP6970115B2 (ja) | デングウイルス複製阻害剤としての置換インドリン誘導体 | |
| JP5850589B2 (ja) | フェニル−３−アザ−ビシクロ［３．１．０］ヘキサ−３−イル−メタノン及び薬物としてのこれらの使用 | |
| CA2570197A1 (en) | Nk1 antagonists | |
| JP4198989B2 (ja) | セロトニン作動性薬 | |
| JP2011520832A5 (OSRAM) | ||
| CN100422175C (zh) | 作为代谢型谷氨酸受体-5调制剂的四环咪唑衍生物 | |
| JP2007508361A5 (OSRAM) | ||
| JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2007508360A5 (OSRAM) | ||
| WO2008059854A1 (en) | Piperidine derivatives or salts thereof | |
| ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
| JP2007500168A5 (OSRAM) | ||
| US9550750B2 (en) | Indoline compounds as aldosterone synthase inhibitors | |
| JP2004507527A5 (OSRAM) | ||
| US20090181952A1 (en) | Compounds useful as alpha7 nicotinic acetylcholine receptor agonists | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| JP4880583B2 (ja) | 新規なベンジル（ベンジリデン）−ラクタム誘導体 | |
| JP2008525513A5 (OSRAM) | ||
| JP2010513489A5 (OSRAM) | ||
| JP2017521367A5 (OSRAM) | ||
| JP2008516959A5 (OSRAM) | ||
| JP2004526721A5 (OSRAM) |